Leerink Partners Cuts Price Target on Aegerion Pharma (AEGR) Following 1Q Miss and Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
After-Hours Stock Movers 05/16: (GSAT) (CYH) (A) Higher; (AEGR) (RLYP) (P) Lower (more...)
May 16, 2016 6:19 PM EDTToday's After-Hours Movers:
Aegerion Pharma (NASDAQ: AEGR) 13.4% LOWER; reported Q1 EPS of ($1.72), $1.14 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $35.7 million versus the consensus estimate of $43 million. Aegerion recorded $26.2 million in net product sales of JUXTAPID® (lomitapide) capsules in the first quarter of 2016, $23.6 million, or 90%, of which was from prescriptions written in the United... More
Aegerion Pharma (AEGR) Misses Q1 EPS Views; Trims FY16 Outlook
May 16, 2016 4:09 PM EDTAegerion Pharma (NASDAQ: AEGR) reported Q1 EPS of ($1.72), $1.14 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $35.7 million versus the consensus estimate of $43 million.
Aegerion recorded $26.2 million in net product sales of JUXTAPID® (lomitapide) capsules in the first quarter of... More
